| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9150579 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| US10570142 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| US9969740 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(11 years from now) | |
| US10414773 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9669033 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| US10981919 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| US10072013 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| US10947244 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(11 years from now) | |
Ukoniq is owned by Tg Theraps.
Ukoniq contains Umbralisib Tosylate.
Ukoniq has a total of 8 drug patents out of which 0 drug patents have expired.
Ukoniq was authorised for market use on 05 February, 2021.
Ukoniq is available in tablet;oral dosage forms.
Ukoniq can be used as relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy, relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy; relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen.
Drug patent challenges can be filed against Ukoniq from 2025-02-05.
The generics of Ukoniq are possible to be released after 26 May, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 5, 2026 |
Drugs and Companies using UMBRALISIB TOSYLATE ingredient
NCE-1 date: 2025-02-05
Market Authorisation Date: 05 February, 2021
Treatment: Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; Relapsed or refractory follicular lymphoma (fl) who have received at least three prior...
Dosage: TABLET;ORAL
UKONIQ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic